Reference : The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporo...
Scientific journals : Article
Business & economic sciences : Special economic topics (health, labor, transportation…)
Human health sciences : Rheumatology
http://hdl.handle.net/2268/40953
The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients.
English
Hiligsmann, Mickaël mailto [Université de Liège - ULg > HEC-Ecole de gestion de l'ULg : UER > Economie industrielle >]
Rabenda, Véronique mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Bruyère, Olivier mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
2010
Health Policy
Elsevier Scientific
96
170-176
Yes (verified by ORBi)
International
0168-8510
Limerick
Ireland
[en] adherence ; compliance ; cost-effectiveness ; economic analysis ; health policy
[en] OBJECTIVES: This study aims to estimate the clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients and the potential cost-effectiveness of adherence-enhancing interventions. METHODS: A validated Markov microsimulation model estimated costs and outcomes (i.e. the number of fractures and the quality-adjusted life-year (QALY)) for three adherence scenarios: no treatment, real-world adherence and full adherence over 3 years. The real-world adherence scenario employed data from a published observational study. The incremental cost per QALY gained was estimated and compared across the three adherence scenarios. RESULTS: The number of fractures prevented and the QALY gain obtained at real-world adherence levels represented only 38.2% and 40.7% of those expected with full adherence, respectively. The cost per QALY gained of real-world adherence compared with no treatment was estimated at euro10279, and full adherence was found to be cost-saving compared with real-world adherence. CONCLUSIONS: This study suggests that more than half of the potential clinical benefits from oral bisphosphonates in patients with osteoporosis are lost due to poor adherence with treatment. Depending on their cost, interventions with improved adherence to therapy have the potential to be an attractive use of resources.
Researchers ; Professionals
http://hdl.handle.net/2268/40953
10.1016/j.healthpol.2010.01.014
Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
HealthPolicy_Hiligsmann.pdfPublisher postprint274.75 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.